Edel del
Barco Morillo
Profesor Asociado CC. Salud
Instituto de Salud Carlos III
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (2)
2020
-
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422
-
Urinary transferrin pre-emptively identifies the risk of renal damage posed by subclinical tubular alterations
Biomedicine and Pharmacotherapy, Vol. 121